Companies /Healthcare

Tempus AI, Inc. Class A Common Stock

NASDAQ: TEM Health Information Services
$64.04
▼ $6.65 (−9.41%) today
Markets closed · 7:11pm ET

Q1 2026 Earnings

Reported May 5, 2026, 4:02pm ET · SEC source
$-0.13
Beat +35.36%
EPS · est. $-0.20
$348.1M
Beat +0.78%
Revenue · est. $345.4M
−9.9%
Trailing market
TEM vs S&P since report
6 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
−3%0+3%May 5May 6report 4:02pm ETearnings+1.3%+1.8%
−3%0+3%May 5May 6earnings+1.3%+1.8%
TEM +1.8%S&P 500 +1.3%
−6%−3%0+3%May 5May 6report 4:02pm ETearnings+1.9%+1.8%
−6%−3%0+3%May 5May 6earnings+1.9%+1.8%
TEM +1.8%NASDAQ +1.9%
−7%0+7%+14%May 4May 13report 4:02pm ETearnings+2.5%−7.8%
−7%0+7%+14%May 4May 13earnings+2.5%−7.8%
TEM −7.8%S&P 500 +2.5%
−7%0+7%+14%May 4May 13report 4:02pm ETearnings+4.8%−7.8%
−7%0+7%+14%May 4May 13earnings+4.8%−7.8%
TEM −7.8%NASDAQ +4.8%
−1.05%
Day of report
−7.53%
Next session
−14.21%
One week
−9.18%
30 days

S&P 500 over the same 30 days: +0.73%.

Did TEM Beat Earnings? Q1 2026 Results

Tempus AI delivered a notably strong first quarter for fiscal 2026, with revenue of $348.12 million growing 36.1% year-over-year and edging past the $345.44 million consensus estimate, while a non-GAAP loss of $0.13 per share came in well ahead of the $0.20 consensus by 35.36%, reflecting meaningful operational progress. The primary engine behind the beat was broad-based momentum across both segments, with Diagnostics generating $261.10 million on 34.7% growth and Data and Applications contributing $87.02 million on 40.5% growth, the latter driven largely by surging biopharma demand for data licensing and AI modeling services. Gross margin expanded to 63.8% from 60.7% a year ago, and Adjusted EBITDA narrowed to a loss of just $2.83 million versus negative $16.17 million in the prior-year period. <a href="https://247wallst.com/investing/2026/05/04/can-nancy-pelosis-favorite-ai-stock-hope-to-regain-its-momentum/">TEM's recent momentum</a> continued into the outlook, as management raised full-year 2026 revenue guidance to $1.59 to $1.60 billion while reaffirming approximately $65 million in full-year Adjusted EBITDA.

Key Takeaways
  • Oncology diagnostic volume growth of 28% year-over-year
  • Hereditary volume growth of 54% (7% adjusted for Ambry pre-acquisition volumes)
  • MRD volume of approximately 6,500 tests, up ~500% year-over-year
  • Insights (data licensing and modeling) revenue growth of 44.1% year-over-year
  • Gross margin expansion to 63.8% from 60.7% year-over-year

“Our strong financial and operational performance this quarter underscores the accelerating demand for our AI-driven diagnostic platform and the immense value of our multimodal data and corresponding AI models.”

Tempus AI CEO, on the earnings call

Forward Guidance & Outlook

Tempus raised full-year 2026 revenue guidance to $1.59 billion–$1.60 billion, representing approximately 25% annual growth, up from prior guidance. The company continues to expect full-year 2026 Adjusted EBITDA of approximately $65 million.

TEM YoY Financials

Q1 2026 vs Q1 2025 · SEC filings Q1 2025 Q1 2026
$-800,000,000$-400,000,000$0$255.7M$348.1MRevenue$155.2M$222.0MGross Profit$-110,487,805$-84,711,000Operating Income$-843,395,847$-125,919,000Net Income
$-800,000,000$-400,000,000$0RevenueGross ProfitOperating IncomeNet Income

TEM Revenue by Segment

Diagnostics$261.1M+34.7%
Genomics
Oncology Testing (Tempus genomics)
Oncology Testing (Tempus Genomics)
Oncology Testing
Hereditary Testing (Ambry Genetics)
Data and Applications$87.0M+40.5%
Data and Services

Figures from SEC filings and company reports. Not investment advice.